For Immediate Release
Toronto, April 20, 2017 – The Leukemia and Lymphoma Society of Canada is proud to congratulate Celator Pharmaceuticals Inc. in receiving the Deal of the Year Award at the 19th Annual Life Sciences BC Awards. The award comes on the heels of the successful development of Vyxeos, the first therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk acute myeloid leukemia (AML) patients.
The clinical trial was conducted in partnership with The Leukemia and Lymphoma Society in both the U.S. and Canada, through its Therapy Acceleration Program (TAP), which has supported the clinical development of VYXEOS beginning in Phase 2.
Over 5000 Canadians living with or in remission from AML have new hope due to the breakthrough in treatment that Vyxeos represents, the biggest in 40 years.
“We are delighted with the Vyxeos translational research outcome and fast tracking of the drug for approval by the FDA,” says Shelagh Tippet-Fagyas, President of the Leukemia and Lymphoma Society of Canada.” “This will help provide access to treatment for Canadians sooner”.
VYXEOS was granted orphan drug status by the FDA and the European Commission for the treatment of acute myeloid leukemia (AML). VYXEOS was also granted Fast Track designation for the treatment of elderly patients with secondary AML.
About the Leukemia & Lymphoma Society of Canada
The Leukemia & Lymphoma Society of Canada is the single largest voluntary health agency dedicated to blood cancers In Canada. LLSC funds lifesaving blood cancer research across the country, and provides free information and support services to patients and caregivers. Our mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
|National Office Location:||For more information please contact:|
|804-2 Lansing Square||Felicitas Adrian|
|Toronto, ON M2J 4P8||647 253-5526 or email@example.com|
|Charitable Registration#: 10762 3654 RR0001||Vice President, Marketing & Communications|
|-30-||The Leukemia & Lymphoma Society of Canada|